{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T22:17:52Z","timestamp":1649024272538},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1097\/mca.0000000000000287","type":"journal-article","created":{"date-parts":[[2015,11,3]],"date-time":"2015-11-03T18:31:54Z","timestamp":1446575514000},"page":"639-641","source":"Crossref","is-referenced-by-count":1,"title":["New oral nitric oxide-dependent medications for patients with coronary artery disease who have persistent angina pectoris"],"prefix":"10.1097","volume":"26","author":[{"given":"Arnon","family":"Blum","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-2-20210204","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1097\/MCA.0000000000000272","article-title":"Influence of trimetazidine and ranolazine on endothelial function in patients with ischemic heart disease.","volume":"26","author":"Rehberger-Likozar","year":"2015","journal-title":"Coron Artery Dis"},{"key":"R2-2-20210204","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1161\/01.cir.0000442015.53336.12","article-title":". Executive summary: heart disease and stroke statistics - 2014 update: a report from the American Heart Association.","volume":"129","author":"Go","year":"2014","journal-title":"Circulation"},{"key":"R3-2-20210204","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1056\/NEJMsa053935","article-title":". Explaining the decrease in U.S. deaths from coronary disease, 1980-2000.","volume":"356","author":"Ford","year":"2007","journal-title":"N Engl J Med"},{"key":"R4-2-20210204","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1093\/eurheartj\/eht296","article-title":". 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology.","volume":"34","author":"Montalescot","year":"2013","journal-title":"Eur Heart J"},{"key":"R5-2-20210204","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2165\/00003088-200645050-00003","article-title":"Clinical pharmacokinetics of ranolazine.","volume":"45","author":"Jerling","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"R6-2-20210204","doi-asserted-by":"crossref","first-page":"447","DOI":"10.2217\/14796678.1.4.447","article-title":"Ranolazine, a new antianginal drug.","volume":"1","author":"Tavazzi","year":"2005","journal-title":"Future Cardiol"},{"key":"R7-2-20210204","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1161\/01.CIR.93.1.135","article-title":"Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts.","volume":"93","author":"McCormack","year":"1996","journal-title":"Circulation"},{"key":"R8-2-20210204","first-page":"1031","article-title":"Can novel therapies for arrhythmias caused by spontaneous sarcoplasmic reticulum Ca release be developed using mouse models Circ","volume":"96","author":"Houser","year":"2005","journal-title":"Res"},{"key":"R9-2-20210204","first-page":"353","article-title":"Update on ranolazine in the management of angina.","volume":"10","author":"Codolosa","year":"2014","journal-title":"Vasc Health Risk Manag"},{"key":"R10-2-20210204","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1016\/j.jacc.2013.02.011","article-title":". Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (type 2 diabetes evaluation of ranolazine in subjects with chronic stable angina).","volume":"61","author":"Kosiborod","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"R11-2-20210204","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jchf.2012.12.002","article-title":". RAnoLazIne for the treatment of diastolic heart failure in patients with preserved ejection fraction: the RALI-DHF proof-of-concept study.","volume":"1","author":"Maier","year":"2013","journal-title":"JACC Heart Fail"},{"key":"R12-2-20210204","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s40265-014-0233-5","article-title":"Defining the role of trimetazidine in the treatment of cardiovascular disorders: some insights on its role in heart failure and peripheral artery disease.","volume":"74","author":"Chrusciel","year":"2014","journal-title":"Drugs"},{"key":"R14-2-20210204","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/FJC.0b013e31814fa9cb","article-title":"Trimetazidine and reduction in mortality and hospitalization in patients with ischemic dilated cardiomyopathy: a post hoc analysis of the Villa Pini dAbruzzo Trimetazidine Trial.","volume":"50","author":"Di Napoli","year":"2007","journal-title":"J Cardiovasc Pharmacol"},{"key":"R15-2-20210204","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1136\/hrt.2010.208751","article-title":"Trimetazidine: a meta-analysis of randomised controlled trials in heart failure.","volume":"97","author":"Gao","year":"2011","journal-title":"Heart"},{"key":"R16-2-20210204","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/MCA.0b013e32832a198b","article-title":". Ranolazine improves endothelial function in patients with stable coronary artery disease.","volume":"20","author":"Deshmukh","year":"2009","journal-title":"Coron Artery Dis"},{"key":"R17-2-20210204","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.atherosclerosis.2012.10.051","article-title":". Effect of ranolazine on arterial endothelial function in patients with type 2 diabetes mellitus.","volume":"226","author":"Lamendola","year":"2013","journal-title":"Atherosclerosis"},{"key":"R18-2-20210204","doi-asserted-by":"crossref","first-page":"A223","DOI":"10.1136\/heartjnl-2013-304613.624","article-title":"The effect of trimetazidine on endothelial function of patients with chronic heart failure.","volume":"99","author":"Shaorui","year":"2013","journal-title":"Heart"},{"key":"R19-2-20210204","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.yjmcc.2013.01.016","article-title":"Mitochondria-mediated cardioprotection by trimetazidine in rabbit heart failure.","volume":"59","author":"Dedkova","year":"2013","journal-title":"J Mol Cell Cardiol"},{"issue":"1-3","key":"R20-2-20210204","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejphar.2013.03.027","article-title":"Mechanisms underlying protective effects of trimetazidine on endothelial progenitor cells biological functions against H2O2-induced injury: involvement of antioxidation and AkteNOS signaling pathways.","volume":"707","author":"Wu","year":"2013","journal-title":"Eur J Pharmacol"}],"container-title":["Coronary Artery Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000000287","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:39:51Z","timestamp":1620959991000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00019501-201512000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":19,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/mca.0000000000000287","relation":{},"ISSN":["0954-6928"],"issn-type":[{"value":"0954-6928","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]}}}